Everett Harris & Co. CA Has $12.98 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Everett Harris & Co. CA reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 0.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 170,241 shares of the medical research company’s stock after selling 678 shares during the period. Everett Harris & Co. CA’s holdings in Edwards Lifesciences were worth $12,981,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in EW. Trueblood Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $206,000. Smithbridge Asset Management Inc. DE lifted its stake in shares of Edwards Lifesciences by 4.2% in the 4th quarter. Smithbridge Asset Management Inc. DE now owns 10,193 shares of the medical research company’s stock valued at $777,000 after purchasing an additional 411 shares during the period. Washington Trust Advisors Inc. grew its holdings in Edwards Lifesciences by 33.2% in the fourth quarter. Washington Trust Advisors Inc. now owns 96,942 shares of the medical research company’s stock worth $7,392,000 after purchasing an additional 24,142 shares during the period. Procyon Advisors LLC increased its position in Edwards Lifesciences by 6.8% in the 4th quarter. Procyon Advisors LLC now owns 6,063 shares of the medical research company’s stock valued at $462,000 after buying an additional 384 shares in the last quarter. Finally, Jacobs & Co. CA raised its stake in Edwards Lifesciences by 3.2% during the 4th quarter. Jacobs & Co. CA now owns 110,665 shares of the medical research company’s stock worth $8,438,000 after buying an additional 3,447 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EW. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Citigroup downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Monday, December 11th. Morgan Stanley upped their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 target price for the company in a research note on Friday, February 2nd. Finally, Evercore ISI cut shares of Edwards Lifesciences from an “outperform” rating to an “in-line” rating and cut their price target for the stock from $80.00 to $77.00 in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $88.50.

Edwards Lifesciences Stock Performance

EW stock traded up $1.73 during midday trading on Wednesday, reaching $95.15. 3,650,661 shares of the company’s stock traded hands, compared to its average volume of 4,078,674. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $95.35. The company has a 50-day moving average price of $85.48 and a two-hundred day moving average price of $75.86. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The firm has a market capitalization of $57.21 billion, a PE ratio of 41.37, a price-to-earnings-growth ratio of 4.62 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the prior year, the firm posted $0.64 EPS. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insider Activity

In other news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the sale, the vice president now owns 34,814 shares in the company, valued at approximately $2,980,774.68. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 14,510 shares of the stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $76.55, for a total value of $1,110,740.50. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,473,434.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 196,859 shares of company stock worth $16,445,296. 1.29% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.